Q:
A:
Pharmaceutical factory PharmaSwiss opens in Belgrade
Belgrade,
5 October 2006
Serbian Minister of Health Tomica Milosavljevic and Swiss Ambassador to Serbia Wilhelm Meier opened today in Belgrade a factory of the Swiss pharmaceutical company PharmaSwiss, which will create 200 jobs.
Director of PharmaSwiss in Serbia Goran Stojanovic explained that the initial production capacity of the factory will be 10 million packets of medicine, and the investment is worth €3.5 million.
Stojanovic said that the price of medicines will not be changed considering the fact that they are already in accordance with regulations valid in the country. He pointed out that society will have great indirect benefits from the opening of this factory because part of the production process will be transferred to Serbia, a large number of people will be employed, and the firm will become an important tax payer.
He said that it is planned that nearly 50% of the production is oriented towards export to EU countries, and recalled that the medicine almodipine, made in the new factory, is already available on the market, and soon other medicines such as diclofenac duo and monopril will be available as well.
Milosavljevic stated on the occasion that this new investment in a very well organised and high-tech area of the pharmaceutical industry will attract other investors to the Serbian market.
He stressed that the production of medicines in the factory is in line with the highest European standards of good production practice, and added that this major investment comes at the right time and in the right manner because new regulations have been implemented in Serbia which are in harmony with European ones.
Ambassador Meier recalled that during the previous two years Serbia and Switzerland have signed two important agreements on promotion and protection of investments and on double taxation avoidance, which have provided better conditions for economic cooperation and investments.
He expressed his expectation that the opening of PharmaSwiss will encourage other Swiss firms to come to Serbia with direct investments.
According to Meier, the Swiss pharmaceutical sector has branches throughout the world, and two million jobs have been created by these investments, including the 200 jobs in Serbia.
PharmaSwiss has been conducting business in Serbia since 2002 and has a 10% share in the Serbian pharmaceutical market.
Stojanovic said that the price of medicines will not be changed considering the fact that they are already in accordance with regulations valid in the country. He pointed out that society will have great indirect benefits from the opening of this factory because part of the production process will be transferred to Serbia, a large number of people will be employed, and the firm will become an important tax payer.
He said that it is planned that nearly 50% of the production is oriented towards export to EU countries, and recalled that the medicine almodipine, made in the new factory, is already available on the market, and soon other medicines such as diclofenac duo and monopril will be available as well.
Milosavljevic stated on the occasion that this new investment in a very well organised and high-tech area of the pharmaceutical industry will attract other investors to the Serbian market.
He stressed that the production of medicines in the factory is in line with the highest European standards of good production practice, and added that this major investment comes at the right time and in the right manner because new regulations have been implemented in Serbia which are in harmony with European ones.
Ambassador Meier recalled that during the previous two years Serbia and Switzerland have signed two important agreements on promotion and protection of investments and on double taxation avoidance, which have provided better conditions for economic cooperation and investments.
He expressed his expectation that the opening of PharmaSwiss will encourage other Swiss firms to come to Serbia with direct investments.
According to Meier, the Swiss pharmaceutical sector has branches throughout the world, and two million jobs have been created by these investments, including the 200 jobs in Serbia.
PharmaSwiss has been conducting business in Serbia since 2002 and has a 10% share in the Serbian pharmaceutical market.
-
Belgrade, 21 July 2025Construction of oil pipeline with Hungary to begin early next year
-
Belgrade/Athens, 17 July 2025Serbia continues to align with EU in field of energy
-
Kostolac, 14 July 2025First solar power plant Petka in Kostolac put into trial operation
-
Belgrade, 11 July 2025Potential for improving cooperation with Belarus in many areas
-
Požega, 5 July 2025Section of Pakovraće - Požega highway officially opened
-
Belgrade, 2 July 2025Technical specifications defined for Serbia-Hungary oil pipeline
-
Belgrade, 30 June 2025IMF confirms Serbia successfully implementing all agreed reforms
-
Belgrade, 27 June 2025Double Taxation Avoidance Agreement with Germany signed
-
Kostolac, 25 June 2025Construction of Kostolac wind farm nearing completion
-
Belgrade, 24 June 2025Government supports request for new postponement of sanctions against NIS